Abstract:Several studies have proposed grading systems aimed at improving the stratification of risk factors for early lung adenocarcinoma, but the repeatability of high‐grade subtypes is unsatisfactory in clinical practice. In this study, we utilized machine learning algorithms and survival models to construct a novel grading system based on the percentages of lepidic, solid, micropapillary lesions and STAS in a cohort of patients with stage I invasive lung adenocarcinoma. Our study has great value in clinical applications since it is more compact, comprehensible, with better accuracy and reproducibility. Background Several studies have proposed grading systems for risk stratification of early‐stage lung adenocarcinoma based on histological patterns. However, the reproducibility of these systems is poor in clinical practice, indicating the need to develop a new grading system which is easy to apply and has high accuracy in prognostic stratification of patients. Methods Patients with stage I invasive nonmucinous lung adenocarcinoma were retrospectively collected from pathology archives between 2009 and 2016. The patients were divided into a training and validation set at a 6:4 ratio. Histological features associated with patient outcomes (overall survival [OS] and progression‐free survival [PFS]) identified in the training set were used to construct a new grading system. The newly proposed system was validated using the validation set. Survival differences between subgroups were assessed using the log‐rank test. The prognostic performance of the novel grading system was compared with two previously proposed systems using the concordance index. Results A total of 539 patients were included in this study. Using a multioutcome decision tree model, four pathological factors, including the presence of tumor spread through air space (STAS) and the percentage of lepidic, micropapillary and solid subtype components, were selected for the proposed grading system. Patients were accordingly classified into three groups: low, medium, and high risk. The high‐risk group showed a 5‐year OS of 52.4% compared to 89.9% and 97.5% in the medium and low‐risk groups, respectively. The 5‐year PFS of patients in the high‐risk group was 38.1% compared to 61.7% and 90.9% in the medium and low‐risk groups, respectively. Similar results were observed in the subgroup analysis. Additionally, our proposed grading system provided superior prognostic stratification compared to the other two systems with a higher concordance index. Conclusion The newly proposed grading system based on four pathological factors (presence of STAS, and percentage of lepidic, micropapillary, and solid subtypes) exhibits high accuracy and good reproducibility in the prognostic stratification of stage I lung adenocarcinoma patients.

Risk Stratification Model for Patients with Stage I Invasive Lung Adenocarcinoma Based on Clinical and Pathological Predictors.

Histopathologic Pattern and Molecular Risk Stratification Are Associated with Prognosis in Patients with Stage IB Lung Adenocarcinoma

Risk Factors of Recurrence for Resected T1aN0M0 Invasive Lung Adenocarcinoma: a Clinicopathologic Study of 177 Patients

Prediction model on disease recurrence for low risk resected stage I lung adenocarcinoma

Prognostic Factors in Curatively Resected Pathological Stage I Lung Adenocarcinoma

Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma

Prognostic Significance of the IASLC/ATS/ERS Classification in Chinese Patients—a Single Institution Retrospective Study of 292 Lung Adenocarcinoma

Proposed novel grading system for stage I invasive lung adenocarcinoma and a comparison with the 2020 IASLC grading system

Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection

[Analysis of the Effect of Different Pathological Subtypes to Prognosis in Stage I Pulmonary Adenocarcinoma].

Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis?: a Clinicopathologic Study of 176 Patients with Pathological Stage IA Lung Adenocarcinoma Based on the IASLC/ATS/ERS Classification.

A Clinicopathologic Prediction Model for Postoperative Recurrence in Stage Ia Non-Small Cell Lung Cancer.

Predictors of Recurrence and Survival of Pathological T1N0M0 Invasive Adenocarcinoma Following Lobectomy

Predictive value of a prognostic model based on pathologic features in lung invasive adenocarcinoma

Preoperative Prognostic Prediction for Stage I Lung Adenocarcinomas: Impact of the Computed Tomography Features Associated with the New Histological Grading System

Clinical, Imaging, and Pathological-Molecular Characteristics Associated with Stage IA Invasive Lung Adenocarcinoma Recurrence After Sub-lobar Resection

Significant difference in recurrence according to the proportion of high grade patterns in stage IA lung adenocarcinoma

A predictive model for identifying candidates for adjuvant chemotherapy based on recurrence risk profile of resected, node-negative (N0) non-small cell lung cancer

Integrating IASLC grading and radiomics for predicting postoperative outcomes in stage IA invasive lung adenocarcinoma

[Prognostic Significance of a Newly Proposed Grading and Scoring System in Stage I Pulmonary Adenocarcinoma].

A biomarker-based prediction model for risk of locoregional recurrence in pathologic stage IIIA-N2 non-small cell lung cancer